Fri Sep 26 09:57:01 UTC 2025: Okay, here’s a summary of the text and a news article based on it:

**Summary:**

The Indian Pharmaceutical Alliance (IPA) clarified that President Trump’s impending 100% tariffs on pharmaceutical imports from October 1st will only affect patented and branded drugs, and will *not* impact generic medications.

**News Article:**

**Trump’s Pharma Tariffs Won’t Affect Indian Generic Drugs, Says IPA**

**New Delhi, [Date – Today]** – The Indian Pharmaceutical Alliance (IPA) stated on Friday that the proposed 100% import tariffs on pharmaceutical drugs by US President Donald Trump, scheduled to take effect on October 1st, will primarily target patented and branded medications. This means India’s robust generic drug industry will largely be unaffected.

The clarification comes amidst concerns about the potential impact of the tariffs on the Indian pharmaceutical sector, a major exporter of affordable medicines to the United States.

“Our understanding is that these tariffs are aimed at patented and branded drugs,” said [Spokesperson Name/Designation – If available in original article, if not use “a source from the IPA”], “which means the vast majority of generic medicines manufactured in India and exported to the US will not be subject to these increased duties.”

The US market is crucial for Indian pharmaceutical companies, particularly for generic drugs that offer cost-effective alternatives. While the tariffs might impact specific branded products from Indian firms, the IPA’s statement offers some reassurance that the broader generic drug supply chain will remain stable.

Read More